Download PDF
Thromb Haemost 2016; 116(03): 405-406
DOI: 10.1160/TH16-07-0523
Invited Editorial Focus
Schattauer GmbH

A two-sided evaluation of benefit and harm from antithrombotic treatment in atrial fibrillation: Balancing clinical application and statistical methodology

Peter Brønnum Nielsen
1   Department of Cardiology, Aalborg University Hospital, Denmark
2   Aalborg Thrombosis Research Unit, Faculty of Health, Aalborg University, Denmark
,
Flemming Skjøth
2   Aalborg Thrombosis Research Unit, Faculty of Health, Aalborg University, Denmark
3   Unit for Clinical Biostatistics and Bioinformatics, Aalborg University Hospital, Denmark
› Author Affiliations
Further Information

Publication History

Received: 11 July 2016

Accepted: 11 July 2016

Publication Date:
11 November 2017 (online)

Also available at
    Permissions and Reprints

 

  • References

  • 1 Wilson MR, Parakramawansha R, Quinn TJ. et al. Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation. Thromb Haemost 2016; 116: 578-580.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Blann AD, Skjøth F, Rasmussen LH. et al. Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2015; 114: 403-409.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Skjøth F, Larsen TB, Rasmussen LH. et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111: 1-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Villines TC, Schnee J, Fraeman K. et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Michalski F, Tittl L, Werth S. et al. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 2015; 114: 1076-1084.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Lane DA, Lip GYH.. Patient's values and preferences for stroke prevention in atrial fibrillation: Balancing stroke and bleeding risk with oral anti-coagulation. Thromb Haemost; 2014; 111: 381-383.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Olesen JB, Torp-Pedersen C.. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?. Thromb Haemost 2015; 113: 1165-1169.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Nielsen PB, Chao T-F.. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost 2015; 113: 1170-1173.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Guo Y, Wang H, Tian Y. et al. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. Thromb Haemost 2016; 115: 184-192.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Philippart R, Brunet-Bernard A, Clementy N. et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2016; 115: 1056-1063.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Paciaroni M, Agnelli G, Ageno W. et al. Timing of anticoagulation therapy in patients with acute is-chaemic stroke and atrial fibrillation. Thromb Haemost 2016; 116: 410-416.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Martinez C, Katholing A, Wallenhorst C. et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016; 115: 31-39.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Singer DE, Chang Y, Fang MC. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
    CrossrefPubMedGoogle Scholar
  • 15 Connolly SJ, Eikelboom JW, Ng J. et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155: 579-586.
    CrossrefPubMedGoogle Scholar
  • 16 Lip GYH, Skjøth F, Nielsen PB. et al. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. Thromb Haemost 2015; 114: 826-834.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Kittelson J, Goldenberg N, Kessler C. et al. Bivariate Evaluation of Thromboembolism and Bleeding In Clinical Trials of Anticoagulants in Patients with Atrial Fibrillation. Thromb Haemost 2016; 544-553.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Fauchier L, Clementy N, Bisson A. et al. Should Atrial Fibrillation Patients With Only 1 Non-gender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?. Stroke 2016; 47: 1831-1836.
    CrossrefPubMedGoogle Scholar
  • 19 Nielsen PB, Larsen TB, Skjøth F. et al. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep 2016; 6: 27410.
    CrossrefPubMedGoogle Scholar